A 400 mg version of oral antiviral FabiFlu is going to be introduced by Glenmark Pharmaceuticals for the treatment of mild to moderate COVID-19 cases. The higher strength will reduce the number of tablets that patients require per day. The 200 mg dosage of FabiFlu required patients to take 18 tablets on Day 1, followed by 8 tablets each day thereafter for a maximum of 14 days. With the new 400 mg version, patients will now have a more relaxed dosage regimen, with 9 tablets required on Day 1 and thereafter 2 tablets twice a day from Day 2 till end of the course.
Dr Monika Tandon, Vice-President & Head, Clinical Development, Global Specialty/Branded Portfolio, Glenmark Pharmaceuticals Limited, said, as the first company to launch Favipiravir in India, they continue to innovate and seek new treatment options for Covid-19 patients. Introduction of higher strength of FabiFlu is in line with the efforts to ensure a smoother experience for patients, by reducing their daily pill burden. The 200 mg dosage of FabiFlu was developed in line with global formulations of the drug Favipiravir. The 400 mg version is a result of Glenmark’s own R&D efforts, she claimed.
